Could it be as simple as SI actually said?
Did everyone listen to the webinar - I thought it was pretty clear.
Ryoncil for kids then talk to FDA about off-label for adults.
Revascor for kids via orphan / fast-track approval.
SI clearly stated MSB will market these on our own.
Royalties from Ryoncil and Revascor + selling the priority review voucher ($100 - $150 million) will go a long way to clearing any outstanding debts and put MSB in a stronger position re: funding via a JV or a CR after Ryoncil approval.
That was my take anyway.
Could it be as simple as SI actually said?Did everyone listen to...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 7663 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 85.5¢ | 3138 | 1 |
View Market Depth
| Last trade - 09.53am 30/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
Day chart unavailable